Subject D56-006

[VileFault]

- WARNING: CLASSIFIED MATERIAL -

This file is the property of the Zeng-Hu Corporate Conglomerate. The contents of this document may only be read, copied, scanned, or otherwise reproduced or interpreted by Zeng-Hu employees with corporate clearance level X9 or above. The unauthorized viewing or reproduction of this document will result in punitive measures up to and including immediate contract termination.

. . . . . . Project Designation Code: D56

. Subject Identification Number: 006

. . . . . . . . . . . . . . . . .-Trial Number: 038

. . . . . . . . -Overseeing Specialists: Megan T. Orr, Simon E. Bard, Josefina H. Royo

. . . . . . . . . . Additional Personnel: Adis H. Brooks, Derrick M. Dutcher

. . . . . . . . . . . . . . . . . . . . .Trial Date: 8/26/2453

Trial Methods:

• A full description of the preparation process for Compound D56 can be found in the supplemental notes of trial 032. As in prior trials, Cryoxadone was manufactured in-house using a base of HG Modified Scatter Factor. A quantity of phoron was also ground into liquid prior to compound synthesis. To attain the required 60ml dose of Compound D56 for this trail, 30ml of Cryoxadone was combined with 30ml of lithium carbonate and 3ml of liquid phoron. A further 2ml of liquid phoron was added to catalyze the bonding of the lithium-phoron group with the Scatter Factor.
  
  
  
  Subject 006 was restrained and placed inside a Model 2.11 Zeng-Hu Pharma DNA Modification Tank, where SE Blocks 1 - 26 were subjected to sustained irradiation for 4 minutes. The subject was then moved to a Type-G Zeng-Hu Pharma Cryogenic Tank into which the 60ml dose of Compound D56 had already been loaded. The genetic damage was measured over time and the results record.

 

Trial Results:

• The irradiation of subject 006 was successful, despite numerous temporary lapses in consciousness during the procedure. Radiation burns were sustained, and significant genetic damage was confirmed. Transfer to the cryogenic tank was completed quickly, though the subject at one point lashed out, damaging an assisting cyborg. The cryotube was running at approximately 100K, and had already suspended an adequate dose of Compound D56 upon subject insertion. Genetic damage healed at a rate far more considerable than that induced by Cryoxadone alone, pointing to the engagement of additional repair pathways by the active lithium-phoron subgroups. A sampling of the subject's DNA taken from the tube after three minutes was indistinguishable from a sample taken and expanded prior to irradiation. In light of these repairs, the subject was removed from the cryotube for observation. Subject 006 regained intellectual lucidity with unusual speed. It is unknown whether this was the result of a heightened emotional state prior to the engagement of cryogenic states, or an effect of Compound D56. The subject was verbal after 24 seconds, but lost this faculty after 49 more. At this point, 73 seconds since exiting the cryotube, the subject lapsed into convulsions and was immediately led to a scanner. The subject experienced acute gastrointestinal distress and considerable renal and cardiac disfunction. Pharmacotherapy was forgone to fully observe the effects of Compound D56. The subject expired following a major cardiac event 29 minutes after leaving the cryotube.
  
  
  
  The symptoms of subject 006 are consistent with acute lithium-phoron overdose, and were likely precipitated by molecules freed from the therapeutic complex after it bonded to the DNA repair enzymes referenced in trial 009. To avoid lethal toxicity, this team recommends the substitution of lithium carbonate for a similarly reactive but less neurologically active substance, such as sodium. This possibility will be discussed and explored further in the September division meeting, and future trials will will be conducted using an adapted version of Compound D56.

 

Supplemental Notes:

• Subject 006 was a 34 year old female of Colonial Arabic decent. Initial psychological testing confirmed satisfactory mental acuity and quickness. The subject had previously been diagnosed with hebephrenic schizophrenia, but was asymptomatic during preliminary testing. Subject 006 was previously treated for a number of terrestrial pathogenic illnesses, including a case of influenza followed by secondary bacterial pneumonia which precipitated moderate bronchial scarring. Subject 006 also had a history of mild lumbosacral spondylosis. Apart from these aforementioned known conditions, no additional abnormalities were detected during bodily scans and blood tests confirmed that the treatment of prior terrestrial illnesses had been sufficiently effective. The blood tests, however, also revealed that the subject had been regularly taking Paroxetine. This compound was removed via standard electrically assisted hemodiafiltration over the course of a two hour period, to avoid unpredictable interactions with Compound D56. Additionally, subject 006's WBC was recorded as 16,890 mcl. This was taken as evidence of a budding xenofungal infection in the subject's right foot, which had suffered a small wound in transit to our facility and appeared visibly inflamed. Pharmacotherapy was forgone to avoid unpredictable interactions with Compound D56.

 

- WARNING: CLASSIFIED MATERIAL -